ACR Metformin Contrast Guidelines: 2026 Protocol Explained

Key Takeaways

• The ACR categorizes metformin-treated patients into two groups based on eGFR thresholds and acute kidney injury status prior to iodinated contrast administration.
• Patients with eGFR ≥30 mL/min/1.73m² and no AKI may continue metformin without holding it before or after IV contrast scans.
• Severe chronic kidney disease (CKD), documented AKI, or arterial procedures with renal embolic risk require holding metformin for 48 hours post-contrast pending renal recheck.
• Targeted pre-contrast screening replaced universal eGFR testing, focusing labs on patients with a history of kidney disease, dialysis, transplants, or documented albuminuria.
• At ContrastConnect, we deliver CMS-compliant virtual contrast supervision that helps imaging centers apply ACR metformin protocols safely across multi-site networks daily.

How the ACR Categorizes Metformin Patients Before Contrast

The American College of Radiology (ACR) sorts metformin patients into two categories before iodinated contrast based on estimated glomerular filtration rate (eGFR) and acute kidney injury (AKI) status, with most patients continuing metformin without interruption and only a smaller group requiring a 48-hour hold and post-contrast renal recheck.

The 2026 update preserves the two-category framework while aligning documentation with the permanent CMS virtual direct supervision rule that took effect January 1, 2026. The protocol also reflects targeted eGFR screening that replaced universal pre-contrast testing, reserving labs for patients with kidney disease, dialysis dependence, transplants, or documented albuminuria. The clinical driver behind every part of the protocol remains the prevention of metformin-associated lactic acidosis (MALA), a rare but serious complication that occurs in roughly 1 to 9 cases per 100,000 patient-years.

We will break down each category, along with the screening criteria and documentation standards, in detail below.

ContrastConnect: Virtual Contrast Supervision That Never Misses

Built by Radiologists | Trusted Nationwide | 55,000+ Monthly Contrast Exams

Built for Imaging Networks:

• Virtual Contrast Supervision: Radiologists provide immediate CMS-compliant supervision through a secure, HIPAA-compliant platform for outpatient facilities and hospital networks.
• Unmatched Experience: Averaging 5–10 contrast reactions daily with documented zero missed responses for 200+ imaging partners.

The ContrastConnect Difference:

• ✓ Radiologist-owned with superior clinical expertise
• ✓ Always-on platform with guaranteed compliance
• ✓ Audit-ready documentation for CMS reviews
• ✓ Cost-efficient alternative to onsite staffing

Safety & Compliance You Trust:

Helping imaging centers reduce cancellations, extend hours, and scale operations without adding on-site radiologists. Response times measured in seconds.

Start Your Coverage Assessment →

Category 1: eGFR ≥30 mL/min/1.73m² Without AKI

Patients with an estimated glomerular filtration rate of 30 mL/min/1.73m² or greater and no evidence of acute kidney injury fall into Category 1. The ACR position is straightforward for this group: metformin does not need to be discontinued before or after intravenous iodinated contrast administration. There is also no obligatory requirement to recheck renal function after the procedure.

The position reflects evidence that continuing metformin in this group does not increase the risk of MALA or contrast-associated kidney injury, as supported by a systematic review and meta-analysis published on PubMed Central. Category 1 covers the majority of outpatient imaging encounters. Patients on stable metformin therapy with normal or mildly reduced kidney function proceed with contrast scans without medication interruption, reducing scheduling friction and eliminating unnecessary patient confusion at intake.

Category 2: AKI, Severe CKD, or Arterial Embolic Risk

Category 2 applies in three scenarios:

• Documented or suspected acute kidney injury
• Severe chronic kidney disease at stage IV or V, defined as eGFR below 30 mL/min/1.73m²
• Arterial catheter procedures that may produce atheromatous or other emboli to the renal arteries

For Category 2 patients, metformin should be temporarily discontinued at or before the procedure. The medication is then held for 48 hours after contrast administration. Resumption is permitted only after kidney function has been reassessed and confirmed to be stable or to have returned to normal. 

This withholding window gives the kidneys time to recover from any contrast effect and prevents metformin from accumulating to dangerous concentrations. Imaging centers should flag Category 2 patients during pre-procedure intake and coordinate with the referring physician on the hold-and-resume plan.

Why the Protocol Centers on Lactic Acidosis Risk

Metformin is cleared almost entirely by the kidneys. When renal function drops acutely, metformin accumulates in the bloodstream, and elevated metformin levels combined with reduced tissue oxygen delivery can trigger lactic acidosis. Iodinated contrast does not directly cause lactic acidosis, but it can occasionally precipitate contrast-associated acute kidney injury, which then impairs metformin excretion. The mechanism is sequential: contrast administration reduces kidney clearance, metformin accumulates, and lactic acidosis follows.

Patient-specific risk factors that compound the danger include congestive heart failure, dehydration, hepatic impairment, sepsis, and excessive alcohol use. Imaging staff should screen for these conditions during pre-procedure assessment, since any of them can shift a patient toward Category 2 management even when baseline eGFR sits above 30. Symptoms of MALA are nonspecific, including malaise, myalgia, somnolence, and abdominal discomfort, so prevention through protocol adherence remains the strongest defense.

Targeted eGFR Screening Replaces Universal Testing

The current ACR position no longer recommends routine measurement of creatinine or eGFR for every patient receiving iodinated contrast. Screening is now targeted to patients with one or more risk factors:

• Known or suspected chronic kidney disease
• Prior acute kidney injury
• Dialysis dependence or kidney transplant
• Single kidney, prior kidney surgery, or kidney cancer
• Documented albuminuria

Patients without these risk factors typically do not need a baseline serum creatinine result before contrast. History of diabetes mellitus and current metformin use are listed as optional considerations, with the final decision left to facility-level protocols. The shift reduces unnecessary lab draws, accelerates patient throughput, and preserves safety for those who genuinely need screening.

Documentation Under the 2026 CMS Supervision Rule

Beginning January 1, 2026, CMS made virtual direct supervision permanent for Level 2 diagnostic tests, including contrast-enhanced CT and MRI, under the 2026 Medicare Physician Fee Schedule Final Rule. Imaging centers that use virtual supervision must document the supervising physician's identity, real-time availability, and the audiovisual platform used. Audio-only connections do not meet the standard.

For metformin management, audit-ready records should capture pre-contrast screening responses, eGFR values where required, the patient's category assignment, the hold-and-resume plan when applicable, and the supervising physician's involvement at the time of administration. Combined documentation supports both ACR clinical compliance and CMS billing requirements, and it produces a defensible record for state audits or accreditation reviews.

How ContrastConnect Supports ACR Metformin Protocol Compliance

The 2026 ACR metformin protocol is operationally simple once the two categories are mapped to the facility workflow. Most patients continue metformin without interruption, while a smaller group with AKI, severe CKD, or arterial embolic risk needs a 48-hour hold and post-contrast renal recheck. The harder question is documentation: imaging centers now need records that satisfy both ACR clinical guidance and the permanent CMS virtual supervision rule.

At ContrastConnect, we provide virtual contrast supervision from specialized radiologists who handle metformin screening, Category 2 decisions, and reaction management on a HIPAA-compliant platform built for multi-site imaging networks. Documentation is captured automatically for ACR and CMS audits.

Start Your Coverage Assessment →

Frequently Asked Questions (FAQs)

Does the ACR require holding metformin for all patients before contrast?

No. The ACR holds metformin only for Category 2 patients, meaning those with documented or suspected AKI, severe CKD with eGFR below 30, or arterial procedures involving renal embolic risk. Patients with eGFR at or above 30 and no AKI continue metformin without interruption around iodinated contrast scans, per current ACR Manual guidance.

How long should metformin be withheld after contrast administration?

For Category 2 patients, the ACR recommends withholding metformin for 48 hours after iodinated contrast administration. Resumption occurs only after the patient's renal function is reassessed and found to be stable or returned to normal. The 48-hour window allows the kidneys to clear contrast agents and reduces the risk of metformin accumulation, which can lead to lactic acidosis.

Is pre-contrast eGFR screening required for every patient on metformin?

No. The ACR now recommends targeted screening based on specific risk factors such as known kidney disease, prior AKI, dialysis dependence, kidney surgery history, or documented albuminuria. Diabetes and metformin use are listed as optional screening considerations rather than automatic triggers, leaving the final call to facility-level protocols and clinical judgment.

What causes metformin-associated lactic acidosis after contrast?

Iodinated contrast can occasionally cause acute kidney injury, which reduces metformin clearance from the body. Accumulated metformin combined with reduced tissue oxygen delivery can trigger lactic acidosis. The condition is rare overall, with incidence estimates around 1 to 9 cases per 100,000 patient-years of metformin therapy, but mortality can be high when it does occur.

How does ContrastConnect help imaging centers apply ACR metformin protocols across multiple sites?

ContrastConnect provides virtual contrast supervision from specialized radiologists who oversee 75,000+ hours of contrast exams monthly, including metformin screening and Category 2 hold decisions. ContrastConnect produces audit-ready records on a HIPAA-compliant platform, helping multi-site networks scale coverage without adding onsite radiologist staff at every location.

‍

‍Note: Information provided is for general guidance only and does not constitute medical, legal, or financial advice. Pricing estimates and regulatory requirements are current at the time of writing and subject to change. For personalized consultation on imaging center operations and virtual contrast supervision, contact ContrastConnect.